ChargePoint Holdings, Inc. Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired ChargePoint Holdings, Inc. (“ChargePoint” or the “Company”) (NYSE: CHPT) securities between June 1, 2023 and November 16, 2023, inclusive (the “Class Period”). Click Here to Join Investigation…. Read MoreJoin Investigation
Eagle Pharmaceuticals, Inc. Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”). … Read MoreJoin Investigation
ACELYRIN, Inc. Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc. (Nasdaq: SLRN) common stock (“Acelyrin” or the “Company”). … Read MoreJoin Investigation
SunPower Corporation Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired SunPower Corporation (“Sun Power” or the “Company”) (NASDAQ: SPWR) securities between March 9, 2023 and October 24, 2023, inclusive (the “Class Period”). Click Here to Join Investigation. … Read MoreJoin Investigation
The Beauty Health Company Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired The Beauty Health Company (“Beauty Health” or the “Company”) (NASDAQ: SKIN) securities between May 10, 2023 and November 13, 2023, inclusive (the “Class Period”). Click Here to Join Investigation…. Read MoreJoin Investigation
James River Group Holdings, Ltd. Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR) securities between August 7, 2023 and November 7, 2023, inclusive (the “Class Period”). Click Here to Join Investigation…. Read MoreJoin Investigation
Paycom Software, Inc. Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired the publicly traded securities of Paycom Software, Inc. (“Paycom” or the “Company”) (NYSE: PAYC) securities between May 3, 2023 and November 1, 2023, inclusive (the “Class Period”). … Read More
Outlook Therapeutics, Inc. Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) securities between December 29, 2022 and August 29, 2023, inclusive (the “Class Period”). Click Here to Join Investigation…. Read MoreJoin Investigation
